吉非替尼不良反应及处理.pptxVIP

Afatinib is an investigational compound and is not yet approved. Its safety and efficacy have not yet been fully established; ?Increased ALT. Mitsudomi T, et al. Lancet Oncol 2010;11:121–8; Maemondo M, et al. N Engl J Med 2010;362:2380–8; Rosell R, et al. Lancet Oncol 2012;13:239–46; Zhou C, et al. Lancet Oncol 2011;12:735–42; Horiike A, et al. ESMO 2012, Abstract 1260P; Yamamoto N, et al. Oral presentation PLS-6. 10th Annual Meeting of Japanese Society of Medical Oncology, 2012.;吉非替尼在临床应用中的相关不良反应（AE）;皮肤及皮下组织异常：;吉非替尼在临床应用中的常见不良反应;痤疮样皮疹 是吉非替尼最常见的不良反应， 主要分布于头面、颈部、后背和前胸部。 发生率为41.4% — 79.7%（样本量范围3